Introduction
When the financial crisis in Greece was at its climax in July 2015, European politicians such as Angela Merkel, David Cameron and the Greek finance minister Yanis Varoufakis were in close contact, and even US president Barack Obama was involved due to potential global economic consequences of the crisis. They were meeting in small groups, holding phone conferences, debating and negotiating over days into the early morning hours 1 . This might have been a rather exceptional situation, but similarly critical and hectic constellations occur again and again in the life of politicians.
It is a highly demanding situation, because the individual politician has to stay sharp, focused, controlled, and be able to make decisions with potentially far-reaching consequences. And he or she often has to keep up this high-functioning state over days and potentially weeks. One historical case where a politician has admitted using pharmacological 'helpers' such as barbiturates and amphetamines to be able to fall asleep and to be fit the next day again is the former British prime minister Anthony Eden 2 , which has been shown to have affected his decision making 2 .
Although life for most people is not as tightly clocked and does not involve decisions about the fate of states or war, the 9 to 5 Monday to Friday work rhythm assumed to be the norm is changing: In the last 150 years, the employment structure and thus the work environment for the majority of workers has changed dramatically: Until about 1911, about equal proportions of workers in the UK worked in manufacturing and services (40% each), whereas in 2011, more than 80% of workers worked in the service industry with less than 10% in manufacturing and agriculture/fishing 3 . This means that the majority of workers now rather use their brains and their minds instead of their muscles, and now maintaining and improving brain function has come into the focus of education and other Governmental departments 4 . This trend is even increased by the digital technology development which is visibly eroding employment in manufacturing and retail as well as having an impact on highly skilled services in multiple areas 5 . month intake. This study focused on the intention of using prescription drugs rather than the specific pharmacological agents. The users reported medications aimed at reducing anxiety/nervousness, antidepressants, stimulants, beta-blocker, and medications aimed at improving memory (antidementiva). Work environments with high prevalence were characterized by high pressure (serious consequences due to small mistakes), work situation with low employments security, a requirement not to show emotions and working at the limit of capabilities. In summary, this report
showed an increasing frequency of the use of pharmacological substances with the aim of improving work-related performance, which amounts to up to 5 million people in Germany (population: 82.6 million). Despite repeated alarming headlines in newspapers [26] [27] [28] [29] [30] [31] [32] [33] , data on the use of cognitive enhancers in work environments from other countries are rare 19 . In student populations, several studies found prevalences between 2 and 25% in various countries, with most studies ranging around 10-15% 19, 34, 35 . Furthermore, most research on the enhancing effects of pharmacological and other enhancing mechanisms such as transcranial electrical or magnetic stimulation (eg. tDCS, tMS) has until now only investigated effects of single (maximum few) intakes on well-defined cognitive tests 36 .
From an ethical and policy perspective, however, the use of neuroenhancing interventions should be carefully considered. On the one hand, impaired cognition due to stress, shift work, or other effects can reduce overall GDP of a nation, be it directly by diminishing productivity or indirectly due to the effects of accidents or long-term effects of stress and work-related disorders such as musculoskeletal and mental disorders (e.g. 37 ). In addition, chronic stress can also negatively affect cognitive function, particularly forms of memory 38 as well as brain volume 39, 40 .
The above mentioned German survey 25 suggests that particularly people who are either worried about their job, working at the limit of their capabilities or in fields where small mistakes can have serious consequences, seem to be particularly prone to using cognitive enhancers 25 , and the users reported the following motives for use: for specific situations (such as exams, giving a presentation, important negotiations, etc., reported by 41%), because work is easier (reported by 35%), I can reach my goals easier (32%), more energy and better mood for other interests (27%), competitive edge at work (12%),
would not be able to do the work otherwise (25%), need less sleep (9%). This is in parallel to studies investigating the motivation of students who consume cognitive enhancers, reporting mainly increasing performance and 'keeping up' (concentration, vigilance, memory, cognitive potential), staying awake for longer periods and a pressure to succeed as well as a way to maintain an active social life [41] [42] [43] . In addition, factors such as overcoming jetlag and improving focus and increasing In patients suffering from neuropsychiatric disorders, deficits can be easily measured, and no-one would dispute the use of drugs or other interventions to improve clinical deficits which might enable patients to lead independent lives, return to work and have a better quality of life and wellbeing.
However, when looking at cognitive enhancement in people without a clear diagnosis of a mental disorder, it is difficult to define the terms "normal cognitive function" and "deficit" (e.g. 21 ): What defines "normal cognitive function"? It might seem rather easy to determine if someone has clear cognitive deficits, for instance, after a stroke or as is the case in chronic schizophrenia. However, it is more difficult in people without a clear medical disorder, but subjective deficits or in people who wish to improve their cognitive performance above their "normal" level or want to maintain their level despite being sleep-deprived or jet-lagged or maybe noticing an aging-related decline. Therefore, it is difficult whether to describe the use of a cognitive enhancing drug in these situations as restoration or as enhancement 21 .
In addition to these definitional questions, there are also questions as to which cognitive enhancing methods are really effective and in which populations (healthy/patients) and for which cognitive domains. It is also important to know whether effects measured in an experimental laboratory setting can be translated into everyday performance and functioning. Besides 'smart drugs' a number of other methods aim at improving cognitive function such as cognitive training, possibly using novel technical methods such as games and smartphone applications, electrical or electromagnetic methods such as transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (TDCS) which aim at directly modulating brain areas or networks to improve cognitive performance.
The aim of this review is to summarize the state of current knowledge on enhancing and restoring cognition in healthy participants and in patients suffering from neuropsychiatric disorders with a particular emphasis on novel findings published in 2014 and in 2015.
Studies on pharmacological cognitive enhancers in healthy volunteers
In general, pharmacological cognitive enhancers used by healthy people can be grouped into several categories: stimulant-types (amphetamines, aimed at improving vigilance, attention, focus, speed of processing), modafinil (which has some similarities to amphetamines, but also differential effects) 46 , drugs used to treat dementia (acting on acetylcholine and/or glutamate, aimed at improving memory) 47 , and due to the link between motivation/mood and cognitive performance, people are also using drugs that improve sleep, reduce anxiety (e.g. benzodiazepines) and improve mood (SSRIs) 25 For prescription stimulants, comprising amphetamines and MPH, the meta-analysis by Ilieva et al.
59
(48 studies) confirmed small but significant effects on inhibitory control and short-term memory, a medium effect on delayed memory, and a borderline significant small effect on working memory in healthy adults. Similarly, the review by Linssen et al. 60 on single dose studies of MPH in healthy volunteers reported clear effects on working memory (particularly with a medium dose (10-20 mg)) and processing speed, weaker effects on learning and memory, attention, and an even weaker effect on decision making and problem solving. Visual learning and memory were not affected across studies, and studies in older adults showed weaker to no beneficial effects compared to younger adults (with the limitation of fewer studies). One study investigated the effect of MPH on the interaction between salience and attentional control, showing that MPH actually increased the distractor cost, i.e. the effect of a salient distractor on attention is increased 61 . The main motives for healthy people to consume pharmacological cognitive enhancers are various (see above) 25, 41 . One study reported that people with subclinical traits related to ADHD, impulsivity and novelty seeking were more prone to using cognitive enhancers 62 . However, it is possible that people self-medicate or at least try to self-medicate for undiagnosed ADHD traits or subjective cognitive deficits 63 as well as for motivational problems 45, 64 and diminished inhibitory control resulting in increased impulsivity 65 . Another study reported similar subjective attention impairments/ADHD symptoms, but also increased omission errors in an attention test in users of (unprescribed) stimulants 66 . However, there is evidence from a number of studies that poor baseline performance predicts cognitive improvement in response to stimulant intake (e.g. [67] [68] [69] [70] ), which might correspond to the dopamine state in the thalamocorticostriatal network 71 93, 94 ). The target of this training varies from circumscribed functional domains such as attention 95 to broad multi-domain cognition 96 . The video-game industry, worth more than £3.9 billion in the UK (2014) 97 , and more than $6.2 billion in the USA (2012) 98 , has developed great strategies to grab the player's attention, create and maintain motivation to play over long time periods and even to tap into brain networks associated with reward and addiction [99] [100] [101] . Certain video games, while not having the explicit aim to improve cognition, seem to have some similar broad effects on cognitive function as specific, targeted "brain training" games 102 , in terms of improving reaction time, speed of response and in some cases attention. In addition, both brain training games and video games are now more and more accessible via the internet, providing a training opportunity for large parts of the population 103 . However, a larger meta-analysis found that the effects of computerized cognitive training in older adults were significant, but relatively small 104 . From a conceptual and scientific perspective and also to target more specific cognitive domains, research has in the last decade aimed at integrating directed cognitive training into video games, using the strategies of "professional" commercial video games and thereby having the potential to overcome the motivational problems evident with classical cognitive trainings (e.g. non-completion rates of > 50% in study settings in a , and most of these are done in cohorts of older adults. There is some evidence that the combination of cognitive and physical training is more efficacious than cognitive training alone (e.g. 116 ). In most of these studies, interventions were done in a group setting, such that the social interaction (if within the group or with members of the teams) was enhanced with any intervention (e.g. 117 ) and can therefore not be separated as factor. In younger adults, however, there is nearly no research on this question. Future studies should focus on, the optimal balance of activities and interventions on cognition, which has until now been neglected.
In the last decades, methods of directly modulating brain activity have been developed with the intention to enhance cognitive performance directly or to increase the efficacy of cognitive training. ), a recent meta-analysis came to the conclusion that it has, if at all, only a weak effect on cognition in healthy subjects 128 and, for instance, in stroke patients 129 , although the former metaanalysis has been criticised for being overly conservative 130, 131 . This finding, however, might in addition be due to heterogeneity associated with a lack of knowledge about, for instance, differential effects of electrode placement and other stimulation parameters 119 . Therefore, research is urgently needed to investigate mechanisms, optimal parameters and objective effects as well as effects of repeated and long-term use, because the unregulated application of DIY neurostimulation devices in this field is increasing 132 .
Using a related and non-invasive approach, methods such as EEG and fMRI based neurofeedback have been shown to enhance the control over or the function of specific brain circuits [133] [134] [135] [136] and enhance cognitive-perceptual processes 137, 138 . However, while the relation between signal (i.e. activity of a brain region or connectivity between brain regions) and function is rather well understood in the case of fMRI neurofeedback, this direct correlation is much less understood in EEG neurofeedback 139, 140 .
Nevertheless, one field that requires more research is the optimal design of training programs (dosage, duration, etc.) and how to ensure the transfer of a practiced skill, if using neurofeedback or other training methods, onto other, more or less related cognitive tasks and, more importantly, into everyday life.
Studies on pharmacological cognitive enhancers in neuropsychiatric disorders (table 1)
Neuropsychiatric disorders are highly prevalent in the general population (18.5% 1-year prevalence in the adult US population) 141 . These disorders and the cognitive disturbances associated with them represent major problems for the ability to work, be productive and the society as a whole 18, 142, 143 .
Neuropsychiatric disorders are characterized by cognitive disturbances including biased attention, 145 and they have serious consequences for the functionality and wellbeing of the individual and the economic development of the society 4, 146 . In some of the neuropsychiatric disorders, cognitive deficits are obvious and have long been targets of treatment, most clearly in dementias and also in ADHD. In others such as depression and schizophrenia, most treatments available until now target the more acute symptoms such as mood or psychosis. However, the cognitive symptoms often persist after remission of the acute symptoms [147] [148] [149] [150] [151] [152] [153] and are associated with serious effects on social and interpersonal functioning, such as fewer than 20% of patients with schizophrenia returning to work after a first psychotic episode 154 . It is now clear that cognitive impairment in schizophrenia and depression is an unmet need and a target for treatment ( 155 . One problem in studies on cognitive enhancing interventions in neuropsychiatric disorders is that a number of studies used clinical scales summarizing global functions associated with cognitive deficits or cognition in everyday situations (e.g. CGI, MMSE in dementia, PANSS in schizophrenia) rather than using specific cognitive tests.
In Alzheimer's disease (AD) and other dementias (or neurocognitive disorders as they are now called in the DSM- 5 156 ), cognitive symptoms are the main aspects 157 . Therefore, research has already since the late 1970s investigated drugs to enhance or even restore cognitive function, particularly memory, using cholinergic mechanisms (e.g. 158, 159 ) resulting in tacrine as the first acetylcholinesterase inhibitor (AChEI, blocking the degradation of synaptic acetylcholine) approved for use in AD 160 . Since then these drugs have been the most successful treatments in AD, even if they are primarily aimed at symptomatic treatment, rather than at the underlying pathology of the disorder. In parallel, research has been trying to develop causal treatments, which would halt the underlying disease processes are, however, still in clinical trials. In the last year, one meta-analysis confirmed the clear positive effects of the AChEIs donepezil, galantamine and rivastigmine as well as the NMDA-receptor antagonist memantine (acting on the glutamate system) on cognition and general functional outcome in AD 161 .
However, using less sensitive subjective measures such as clinical global impression, only donepezil was clearly superior to placebo, with rivastigmine improving only clinical impression. Three recent studies [162] [163] [164] have shown that treatment with cholinesterase inhibitors not only improves functional outcome, but also is cost-effective. Therefore early detection and early effective treatment with
AChEIs is important. Early detection will become even more important when neuroprotective drugs and drugs targeting the disease process causally will become available. From a health-economic perspective, a recent study showed that treatment with cognitive enhancing drugs (ACHEI and memantine) in AD clearly reduced total costs (direct and indirect) compared to no treatment 165 . In one study, the beneficial effect of donepezil on cognition and overall outcome was not correlated with hippocampal volume 166 . In contrast, in untreated patients cognitive deficits and hippocampal atrophy were correlated, whereas this was not the case in donepezil treated patients 166 . One study showed also improvement in gait performance due to donepezil treatment in AD 167 . In 2014 and 2015, there were furthermore a handful of studies using galantamine confirming its beneficial effect on some cognitive domains for a duration of 6-12 month, and thereafter the drug slowed the progression of deterioration [168] [169] [170] . In terms of novel treatment approaches published in 2014 and 2015, particularly histamine H3 receptor antagonistic approaches have been tested [171] [172] [173] , as well as rapid acting insulin 174 . Further studies investigated the effects of benzoate (aiming at enhancing NMDA receptor function) showing an improved cognitive performance and global clinical impression in a randomized placebo-controlled study over 24 weeks in 60 patients 175 .
In Dementia with Lewy Bodies, a neurodegenerative disorder with a different pathophysiology and different symptom profile compared to AD, a recent meta-analysis 176 found a beneficial effect of the ACHEIs donepezil and rivastigmine for cognitive functioning as well as for other symptoms such as visual hallucinations, but only limited evidence for other drugs targeting cognition such as galantamine and memantine.
Next to the dementias, schizophrenia is the neuropsychiatric disorder where cognitive deficits have long been described 177, 178 and are considered to be an important target for treatment 179 due to their relationship to functionality. However as yet, the relationship between antipsychotic treatment and cognition in schizophrenia is mixed 180 , with some antipsychotics coming out as being superior in certain domains but apparently impairing function in another domain. For example, verbal fluency was shown to be improved by clozapine, but in contrast, verbal memory was impaired by clozapine (atypical antipsychotic drug primarily acting on serotonine receptors, 5HT2A 181 ), in comparison to other antipsychotics 180, [182] [183] [184] . Recently, research has aimed at developing drugs that reduce so-called positive symptoms (i.e. hallucinations, psychosis) and also improve cognition. The first drug promising to fulfil these aims is lurasidone, which has a mixed pharmacology with antagonistic effects on dopamine D2 receptors and the 5-HT7 serotonergic receptor, and partial antagonistic effects on the 5-HT1A serotonergic receptor 185 . In comparison to quetiapine, it has been shown to dose-dependently improve cognition measured with a composite measure as well as skills-based everyday functioning 186 .
However, the long-term effects of this novel drug on cognition and everyday functioning, and particularly work and social functioning, have not yet been shown although it was only approved in the US in 2010 and in the EU in 2014. The last 10 years have seen a number of trials using drugs initially developed as antidementive drugs (ACHEIs) in schizophrenia. However, the initially positive reports could not be replicated in bigger samples or the effects in memory, attention and processing speed were relatively small [187] [188] [189] [190] . Similarly, compounds aiming more specifically at nicotinic acetylcholine receptors and their subtypes showed relatively small effects in attention, working memory, planning and memory 191, 192 . In parallel, research tried to modify the glutamatergic system in the hope of improving cognitive deficits in schizophrenia based on the hypothesis that a glutamatergic However, amongst others, a couple of recent meta-analyses showed no significant effect of drugs that positively modify glutamatergic signalling or acting as agonists or co-activators on glutamatergic receptors 188, [194] [195] [196] . Similarly, the use of antidepressants aiming at manipulating the serotonergic system to improve cognition in schizophrenia was not successful in improving cognition, but did improve depressive symptoms (e.g. 197 ). Similar negative results were reported on other pharmacological mechanisms such as a H3 histamine receptor antagonist 198 , monoamineoxidase Binhibitor rasagiline 199 . One study in 71 patients showed improvements using the estrogen receptor modulator raloxifene in measures of memory in a placebo-controlled cross-over study 200 which, however, remains to be replicated (see no significant effect in a recent study in 42 women 201 ). One other review collated support for a combined treatment with galantamine and memantine, although this suggestion has yet to be conclusively tested 202 . Modafinil showed in a meta-analysis of 8 randomized-controlled studies including 372 patients a small improvement in negative symptoms without worsening positive symptoms, but also without strong difference from placebo in direct tests of cognition 203 . One study combined cognitive training in schizophrenia patients with modafinil compared to placebo, but without an additional effect of modafinil 204 . Using modafinil in patients with schizophrenia who are high functioning or early in the course may well yield beneficial effects [205] [206] [207] .
However, to date, most of the studies were conducted using chronically ill patients with relatively severe cognitive deficits. There are reasons to believe that with earlier treatment the development of cognitive impairments can be stopped or even reversed which might be easier to achieve than to repair damage that has already occurred 208 . And in addition, the lack of consistent results could be due to the neurobiological heterogeneity of schizophrenia as diagnostic category, meaning that with neurobiological criteria for subcategories treatment responders to specific and different cognitive treatments might be identified.
In affective disorders, including particularly major depressive disorder (MDD) and bipolar disorder, there has been a strong move to finding mechanisms that can help alleviate the cognitive symptoms 155 that frequently remain even after the main affective symptoms are remitted 151, 209 and which strongly impact on functional outcome (review in 210 ). A recent review 211 summarised 26 studies focusing on the treatment of cognition in depression. In this review, the NMDA-receptor antagonist memantine did not show a cognition enhancing effect. Two other drugs typically used in the treatment of cognitive deficits in dementia, galantamine and donepezil, did not suggest a clear benefit for cognitive impairments in depressed older patients (with the limitation that more studies are needed for these drugs). Vortioxetine, a serotonergic antidepressant with reuptake-inhibiting and specific 5HT receptor activity, has received approval from the European Medicines Agency (EMEA) supporting the beneficial effect on cognitive functions in depression based on a big multicenter study in 602 patients 212 and it is currently in the process of being assessed by the US Food and Drug Administration for the specific indication of improving certain aspects of cognitive function in adults with MDD 213 . ). Vortioxetine, however, had rather consistent beneficial effects on memory in stressed and normal animals 216 . In animal models of executive function, both serotonergic and noradrenergic mechanisms have shown to improve stress-induced impairments 216 . Yet another mechanism of improving cognition in depression is the application of erythropoietin, which in one study showed a potential beneficial effect on clinical outcome as well as verbal learning (RAVLT) in MDD 217 and on reaction time in remitted bipolar disorder 218 . In parallel to the idea to use stimulants to improve cognition in healthy people and in In the field of addiction, the use of modafinil and stimulants has until now been mainly investigated for the treatment of the primary symptoms, i.e. addiction, craving, rather than for cognitive effects 225 .
Attention-deficit-hyperactivity (ADHD) disorder is a paradigmatic disorder where stimulants (amphetamines), have long been used and are established treatments for the primary symptoms as well as for cognitive symptoms 226, 227 -cognitive and primary symptoms are very closely linked in ADHD.
Problems in sustained attention are core cognitive deficits, which can be improved by methylphenidate in both ADHD patients and healthy volunteers 228, 229 . In adult ADHD patients, stimulants have been shown to improve sustained attention, inhibition and verbal learning 227 . In 2014 and 2015, the most prominent research investigated an ongoing discussion about effects of stimulant treatment on general development, particularly reduced height and/or weight. Some studies resulted in small effects of stimulant treatment on the development of height and/or weight 230, 231 in children, but some studies also found no effect 232 , review 233 . Considering that ADHD itself seems to be associated with increased body weight 234 , it could mean that the medication may normalize body development in ADHD.
However, there is insufficient evidence to determine this as yet.
A few studies investigated the effect of cognitive enhancers in other neuropsychiatric disorders such as Fragile X-syndrome 235 (beneficial effect of 1-year treatment with memantine on cued verbal memory recall, but not free recall), traumatic brain injury 236 (beneficial effect of methylphenidate on fatigue and psychomotor speed), post-radiation impairments in cancer patients 237 (24 week treatment with donepezil, improved in some cognitive domains, stronger effect in more impaired patients) and a meta-analysis of 10 (mostly small) studies using modafinil in neurological disorders (Parkinson's disease, multiple sclerosis, traumatic brain injury) reported rather inconsistent effects (trend towards improved excessive daytime sleepiness, but no effect on depression), concluded that more research in this field is needed 238 .
One field that is gaining more attention is the combination of cognitive enhancers with psychotherapy, for instance in anxiety disorders. Particularly D-cycloserine (modulating (enhancing) the NMDA glutamate receptor) has been investigated with overall more positive than negative studies, but also other drugs are showing some positive effects (recent reviews: [239] [240] [241] [242] [243] ). Another approach is the combination of pharmacological cognitive enhancers with cognitive training. A recent study in patients with schizophrenia combined modafinil with cognitive training in a placebo-controlled design over 10 days 204 . There was a clear effect of cognitive training on measures of attention, working memory, learning and executive function, but no additional effect of modafinil compared to placebo.
However, both these applications of cognitive enhancers (psychotherapy, cognitive training) are still in an experimental stage, requiring more systematic and randomized controlled studies. 
Non-pharmacological interventions to enhance cognitive performance in neuropsychiatric disorders
In the field of neuropsychiatric disorders, there are fewer studies investigating the effects of cognitive training and other interventions on cognition, although at least in mild to moderate neurocognitive disorders the benefits of, for instance, physical exercise combined with computerized cognitive training seem to be comparable or only moderately weaker than the improvements in healthy older adults [250] [251] [252] , and that even in patients with manifest, up to moderate AD a training of specific memory functions is possible and can be maintained over months 253, 254 , although the effects of specific cognitive training compared to multi-domain cognitive stimulation in a recent meta-analysis were weaker (moderate effect size for multi-domain cognitive stimulation) 255 .
In the field of schizophrenia, there have been a couple of studies applying computerized as well as app-based and video-game based trainings with mostly beneficial effects such as an improvement in cognitive flexibility as well as in everyday functioning after cognitive training using a specifically designed video game for 4 weeks. The recent study by Sahakian et al. 21 used a neuroscientific approach to brain app development, combined with an integrative approach, including neuroscientists, a game developer and service users with schizophrenia. Game play with the Wizard memory app improved episodic memory and learning and patients' social, occupational and psychological functioning. In addition, motivation remained high throughout the 8 hours of training over 4 weeks 21 .
In general, the evidence is quite strong that cognitive training (also known as cognitive remediation)
can improve cognition and everyday outcome in schizophrenia [256] [257] [258] , resulting in neuroplastic changes in brain activation 259, 260 . A recent study showed improvements even in patients diagnosed with schizophrenia without clear insight into their cognitive deficits 261 . In addition, research has recognized the importance of cognitive training particularly in patients early in the course of schizophrenia, after a first psychotic episode, to maintain and strengthen the patients' resources already early in the course and to enable a rapid re-integration into social and work environments [262] [263] [264] , with some studies successfully targeting also social cognitive functions such as theory of mind directly 265 , whereas a recent review showed transfer effects of cognitive training onto social functions 266 . However, despite this rather strong overall body of evidence, only few treatment guidelines include neurocognitive training into their recommendations 267 , whereas the American Psychiatric Association, for instance, considers cognitive remediation therapy as 'experimental and cannot yet be recommended as part of routine practice' (although the last guideline is from 2004) 268 . However, one study in a group of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 u n e d i t e d m a n u s c r i p t patients with mixed mental disorders showed that in patients who had failed in a trial of supported employment a specific cognitive training could increase their chance of employment to 60% 269 .
In other neuropsychiatric disorders, there are fewer studies investigating the effects of cognitive training (e.g. in PTSD 270 , stress-related exhaustion 271 , etc.) whereas in mood and anxiety disorders, for instance, training modules still have to be developed 272 .
RTMS as non-invasive stimulation method in depression has proven efficacious to improve clinical symptoms 273, 274 . In contrast, in studies investigating the effect of rTMS on cognition in depression the findings are more mixed (meta-analysis 275 , newer study 276 ) , with executive functions, memory and attention each being improved in two or more studies. One study suggested a baseline effect, with patients with higher executive function performance at baseline benefitting more 276 than patients with lower baseline performance.
Summary and conclusion
Overall, maintaining, restoring and improving cognitive performance is of increasing relevance with respect to work and economic environments as well as general quality of life and health.
From a neuroethical perspective, it is important to consider both the positive but also the negative forces, for example excessive stress or indirect coercion, on healthy individuals to enhance themselves at school, university or work 277 .
In people suffering from neuropsychiatric disorders, the evidence for potential pharmacological interventions for improving cognition is growing, but fewer studies have investigated nonpharmacological interventions. However, the potential gains due to interventions might even be larger than in healthy volunteers. It may be that combining pharmacological and non-pharmacological means of enhancement might produce greater benefits in terms of cognition and wellbeing for those with neuropsychiatric disorders.
Viewing the increasing lifestyle use of cognitive enhancing drugs from a policy perspective, there is an urgency for a public-private partnership between the government and the pharmaceutical industry to evaluate the long-term safety and efficacy of drugs such as modafinil in healthy people. These types of study could eliminate the potential harms of the dangerous practice of internet purchasing of prescription only cognitive enhancing drugs, with its potential harms.
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